Page 5 - Peter Greenleaf News Today

19.09.2022 - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced that the European Commission (EC) has granted marketing ... Seite 1

Press release content from Business Wire. The AP news staff was not involved in its creation.

Positive CHMP opinion is based on a comprehensive submission including data from the pivotal AURORA 1 efficacy study and the AURORA 2 continuation study, demonstrating voclosporin to be safe and well

British Columbia-based Aurinia Pharmaceuticals Inc. announced that its voclosporin drug has been recommended for marketing authorization.

Volker Knappertz, MD, as Executive Vice President, Research and Development, to lead the consolidated R&D function and to further enhance and advance the Aurinia pipelineScott Habig, as Chief Commercial Officer, to lead and enhance Aurinia’s commercial capabilities, replacing Max Colao, who led the formation of the...

14.07.2022 - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced the appointment of three seasoned leaders to the ... Seite 1

10.05.2022 - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the first quarter ended March 31, 2022. Amounts, unless specified otherwise, are expressed in U.S. dollars. Net product revenues were $21.6 ...

Aurinia Pharmaceuticals Inc. (NASDAQ:NASDAQ:AUPH) Q1 2022 Earnings Conference Call May 10, 2022, 08:30 AM ET Company Participants Dana Lynch - Director of Corporate Communications &...

Press release content from Business Wire. The AP news staff was not involved in its creation.

The biotech's underwhelming revenue guidance for 2022 is causing some shareholders to throw in the towel today.